SerpinB9与肿瘤关系及其在皮肤肿瘤领域的研究进展

死亡受体途径和穿孔素/颗粒酶途径是免疫系统杀伤肿瘤细胞的主要机制，SerpinB9是已知的人体中唯一能够抑制颗粒酶B(granzyme B，GrB)水解活性的蛋白。研究表明，肺癌、前列腺癌等肿瘤细胞可通过表达SerpinB9抵抗细胞毒性淋巴细胞通过穿孔素/GrB介导的杀伤作用。在皮肤肿瘤领域，恶性黑色素瘤、鳞状细胞癌及皮肤淋巴肿瘤细胞中均可检测到SerpinB9表达，并通过促进免疫逃逸、抵抗免疫治疗、影响肿瘤微环境等多种途径促进肿瘤进展。此外，已有研究证实SerpinB9抑制剂可抑制恶性黑色素瘤生长，表明SerpinB9可作为潜在的抗肿瘤治疗靶点。本文将对SerpinB9在皮肤肿瘤领域的研究现状进行综述。

Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors

Death receptor pathway and perforin/granzyme pathway are the main mechanisms for immune system to kill tumor cells. SerpinB9 is the only known human protein that is able to inhibit the proteolytic activity of granzyme B (GrB). Expression of SerpinB9 has been observed in various human tumors, such as lung cancer and prostate cancer, and SerpinB9 can protect tumor cells from cytotoxic lymphocytes-mediated killing through the perforin/GrB pathway. In skin tumors, SerpinB9 expression has been detected in cells of malignant melanoma, cutaneous squamous cell carcinoma, cutaneous lymphomas, in which SerpinB9 contributes to tumor progression by mediating immune escape, resistance to immunotherapy and interference of the tumor microenvironment. In addition, researches have shown that inhibitor of SerpinB9 could retard the growth of melanoma, indicating the potential anti-tumor therapeutic application of SerpinB9 inhibition. The research status of SerpinB9 in skin tumors is reviewed in this paper.